Practice Updates: Hospital Disaster Preparedness, FDA Removal of Boxed Warning on Varenicline and Bupropion

Stay up to date with ACOG's authoritative clinical guidance and helpful patient education materials. The following provides Practice Updates for November and December. 

TOPIC SPOTLIGHT

Featured Committee Opinion 726: Hospital Disaster Preparedness for Obstetricians and Facilities Providing Maternity Care

This Committee Opinion outlines the key components to preparation and communication for the successful management of obstetrical care during emergencies. It is recommended that hospitals develop strategies in advance, to prepare for issues that are likely to occur in an emergency, The Committee Opinion includes two new components of planning and coordination to integrate into existing strategies: adherence to ACOG and Society for Maternal-Fetal Medicine’s Levels of Maternal Care designations; and communication using a common terminology, like Obstetric Triage by Resource Allocation for Inpatient (OB-TRAIN). Both systems enable quick categorization of patient needs and transport of obstetric patients to appropriate facilities in an emergency, ensuring women have access to the right care at the right time.

Committee Opinion 726: Hospital Disaster Preparedness for Obstetricians and Facilities Providing Maternity Care is available in the December issue of Obstetrics & Gynecology.

 

Featured Practice Advisory: FDA Removal of Boxed Warning on Varenicline and Bupropion

ACOG has issued a Practice Advisory in response to a December 2016 Drug Safety Communication from the US Food and Drug Administration (FDA). The FDA Communication revises the description of mental health side effects of some medications used for smoking cessation, specifically varenicline and bupropion. As a result of this review, the FDA removed the boxed warning for serious mental health side effects from the labels on these medications.

ACOG recommends that ob-gyns continue counseling women regarding the risks of smoking, benefits of smoking cessation and resources available to assist in smoking cessation, which may involve the use of these medications. Ob-gyns should be aware of updated information on the benefits and risks associated with these medications.

See the full Practice Advisory: FDA Removal of Boxed Warning on Varenicline and Bupropion.

 

Zika Information

ACOG’s Zika webpage

Interim Guidance for Care of Obstetrics Patients During a Zika Virus Outbreak

ACOG Zika Toolkit, including patient education video, infographic, and assessment web tool endorsed by CDC

CDC’s Pregnancy and Zika Testing Clinical Algorithm

CDC Zika Virus Website

State Health Department Contact list for ob-gyns (members only) for questions on CDC's Zika Registry and testing

CDC Zika Pregnancy Hotline for Health Care Providers: Ob-gyns can contact the CDC Zika Pregnancy Hotline at 770-488-7100, or email ZikaPregnancy@cdc.govfor any concerns related to clinical management or the US Zika Pregnancy Registry.

Office of Population Affairs' Zika Toolkit


LIST OF NEW PRACTICE PUBLICATIONS DECEMBER 2017

 

New Committee Opinions

See all Committee Opinions

                                                                                                                                 

New Practice Bulletins (members only)

See all Practice Bulletins

  

New Title: Clinical Updates in Women's Health Care (members only)

See all Clinical Updates Titles

 

New & Recently Updated Patient Education Pamphlets (members only)

See all Patient Education Pamphlets

 

New Patient Education Fact Sheets

 

Frequently Asked Questions (FAQs) for Patients

 

See all Frequently Asked Questions

American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998